---
title: "Abbott Laboratories Stock Underperforms Monday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285993627.md"
description: "Abbott Laboratories (ABT) shares fell 2.09% to $82.56 on Monday, marking its second consecutive day of losses, while the S&P 500 and Dow Jones both rose 0.19%. The stock is currently 40.63% below its 52-week high of $139.06. In comparison, competitors like Johnson & Johnson and Pfizer saw slight gains, while Merck experienced a minor decline. Trading volume for Abbott was 16.2 million, surpassing its 50-day average of 12.6 million."
datetime: "2026-05-11T20:36:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285993627.md)
  - [en](https://longbridge.com/en/news/285993627.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285993627.md)
---

# Abbott Laboratories Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Abbott Laboratories (ABT) slipped 2.09% to $82.56 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.19% to 7,412.84 and the Dow Jones Industrial Average rising 0.19% to 49,704.47.

This was the stock's second consecutive day of losses.

Abbott Laboratories closed 40.63% below its 52-week high of $139.06, which the company reached on June 24th.

The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) rose 0.05% to $221.43, Pfizer Inc. (PFE) rose 0.51% to $25.81, and Merck & Co. Inc. (MRK) fell 0.09% to $111.28.

Trading volume (16.2 M) eclipsed its 50-day average volume of 12.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 11, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-11-26 1636ET

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Abbott Laboratories Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/285725373.md)
- [Rayburn West Financial Services LLC Buys Shares of 16,587 Abbott Laboratories $ABT](https://longbridge.com/en/news/286395934.md)
- [NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies](https://longbridge.com/en/news/286239950.md)
- [Abbott’s BurstDR Trial Targets Painful Diabetic Neuropathy: What Investors Should Watch](https://longbridge.com/en/news/285754862.md)
- [Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)](https://longbridge.com/en/news/285317649.md)